Pygeum: Enlarged Prostate (BPH) Evidence

Table of Contents

1. What BPH Is, in Plain Terms
2. How Symptoms Are Measured
3. The Cochrane Review, Number by Number
4. The 1990 Multicentre Placebo Trial
5. Once Versus Twice Daily: the 12-Month Study
6. Why the Trials Are Hard to Read
7. What Later Reviews Concluded
8. Where Standard Treatment Sits
9. What Has Never Been Tested
10. Key Research Papers
11. Connections

What BPH Is, in Plain Terms

Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate gland. The Cochrane reviewers described it as an enlargement that "can lead to obstructive and irritative lower urinary tract symptoms". Obstructive symptoms come from a narrowed outflow: a weak or interrupted stream, straining, and a sense that the bladder has not emptied. Irritative symptoms come from a bladder working against resistance: urgency, frequency and waking at night to urinate.

It is common. A 2023 evidence review reported that lower urinary tract symptoms from BPH affect about a quarter of US men, nearly half of them at least moderately, and identified a sedentary lifestyle, high blood pressure and diabetes as factors that increase the risk of symptoms. A 2011 systematic review reported that symptoms may affect up to 30% of men in their early seventies, that symptoms can improve without treatment, but that the usual course is slow progression, with acute urinary retention in about 1% to 2% of men with BPH each year.

That natural tendency to fluctuate is one reason placebo groups in BPH trials often improve too, and why a placebo comparison matters so much.

Back to Table of Contents

How Symptoms Are Measured

BPH trials use a small set of standard measurements. Knowing what each one means makes the results easier to read.

• International Prostate Symptom Score (IPSS) — a questionnaire scored 0 to 35 covering emptying, frequency, intermittency, urgency, weak stream, straining and night-time urination. Higher is worse. The 2023 review called it the best way to track symptoms.
• Peak urine flow (Qmax) — the fastest flow rate during urination, in millilitres per second. A narrowed outflow lowers it.
• Residual urine volume — how much urine is left in the bladder straight after urinating.
• Nocturia — the number of times a man gets up at night to urinate.
• Quality of life — usually a single question on how a man would feel if his symptoms stayed as they are.

The Cochrane review noted that the pygeum trials "rarely reported outcomes using standardized validated measures of efficacy". Trials that measured symptoms in their own ways could not be combined, which is part of why only 6 of 18 trials could be pooled for the main combined outcome.

Back to Table of Contents

The Cochrane Review, Number by Number

Timothy Wilt, Areef Ishani and colleagues at the Minneapolis Veterans Affairs centre searched MEDLINE, EMBASE, the Cochrane Library and the specialist phytotherapy database Phytodok, checked bibliographies and contacted manufacturers and researchers. They included randomised trials in men with BPH that compared a pygeum preparation, alone or in combination, with placebo or another BPH medicine for at least 30 days.

Who and how long

• 18 randomised controlled trials, 1,562 men.
• 17 of the 18 were double-blinded; only 1 described how treatment allocation was concealed.
• Average duration 64 days; the shortest 30 days, the longest 122 days.
• No trial compared pygeum with an alpha-blocker or a 5-alpha-reductase inhibitor.

What was found against placebo

• Combined symptoms and flow: effect size −0.8 standard deviations (95% CI −1.4 to −0.3; 6 studies), which the reviewers called "a moderately large improvement".
• Overall symptoms: men on pygeum were more than twice as likely to report improvement (risk ratio 2.1; 95% CI 1.4 to 3.1).
• Nocturia: reduced by 19%.
• Residual urine volume: reduced by 24%.
• Peak urine flow: increased by 23%.

Side effects and dropouts

• Adverse effects were mild and comparable to placebo.
• Overall dropout was 12%: 13% on pygeum, 11% on placebo, 8% on other controls.

The same team published the analysis in The American Journal of Medicine in 2000, concluding that pygeum "modestly, but significantly, improves urologic symptoms and flow measures". In a broader 2000 review of all BPH phytotherapies, they wrote that pygeum (17 studies, 900 men in that analysis) "may be a useful treatment option", but that inadequate reporting of outcomes limited their ability to estimate its safety and efficacy.

Back to Table of Contents

The 1990 Multicentre Placebo Trial

One of the larger placebo-controlled trials was run in 8 centres in Germany, France and Austria and published in 1990.

• Participants: 263 men with urination problems due to BPH.
• Treatment: 50 mg pygeum extract or placebo, one capsule morning and evening, for 60 days.
• Measurements: mainly objective ones — residual urine, urine flow, and careful counts of daytime and night-time urination — plus patients' own ratings of their symptoms.
• Result: the quantitative measures differed significantly between groups, and the subjective symptoms improved significantly. At the end, urination had improved in 66% of the pygeum group and 31% of the placebo group (p < 0.001).
• Side effects: gastrointestinal effects in 5 patients; treatment was stopped in 3.

The trial is a good example of the strengths and weaknesses of the evidence base. It was double-blind, multicentre and placebo-controlled, which is more than many herbal trials manage. But it lasted two months, used an overall "improved or not" judgement as its headline result rather than a validated score, and its lead author was affiliated with the extract's manufacturer.

Back to Table of Contents

Once Versus Twice Daily: the 12-Month Study

A French trial published in 1999 asked a practical question: does one 100 mg dose a day work as well as two 50 mg doses?

• Phase 1 (2 months, double-blind): 209 men completed the comparison of 50 mg twice daily with 100 mg once daily. Starting IPSS was 17 in both groups.
• IPSS improved by 38% on the twice-daily schedule and 35% on once-daily; quality of life improved by 28% in both.
• Peak flow rose by 1.63 mL/s (16%) and 2.02 mL/s (19%) respectively.
• Phase 2 (10 months, open-label): 174 men continued on 100 mg once daily. After 12 months the IPSS had fallen from 16 to 9 (−46%), half of the men had an IPSS below 8, and mean peak flow had increased by 1.65 mL/s (15%).
• The safety profile was similar between groups and across both phases.

What the trial shows is that the two schedules performed alike. What it cannot show is how much of the improvement was due to pygeum, because neither phase had a placebo group. In BPH, symptom scores in placebo groups commonly improve as well, so an open-label fall in IPSS is not by itself evidence of a drug effect.

Back to Table of Contents

Why the Trials Are Hard to Read

The Cochrane reviewers listed the problems themselves, and later reviewers added to the list.

1. Small and short. The average trial ran just over two months. BPH is a condition of years.
2. Allocation concealment. Only 1 of 18 trials reported how it stopped investigators knowing in advance which treatment the next man would get — a known source of bias.
3. Varied preparations and doses. Different extracts, doses and combinations were pooled.
4. Non-standard outcomes. Many trials did not use validated symptom scores, and many "did not report results in a method that permitted meta-analysis".
5. No active comparator. No trial compared pygeum with the drugs men are usually offered.
6. Product specificity. A 2002 review argued that because extraction methods and raw materials differ, "one product might have clinical efficacy while another might not", and that meta-analyses combining different products "may be misleading".

Back to Table of Contents

What Later Reviews Concluded

Reviews after 2002 rarely added new pygeum trials; they reinterpreted the same body of evidence, and they diverged.

• Dreikorn (2000, 2002): by strict evidence-based criteria the data were inconclusive; the 4th International Consultation on BPH and German guidelines had not recommended phytotherapy, and further randomised placebo-controlled trials were needed.
• Morán and colleagues (2013, Spain): a systematic review of 40 articles found many studies in favour of phytotherapy but inconsistent conclusions because of small numbers, lack of placebo control or short follow-up; it concluded that the evidence did not support phytotherapy for BPH.
• Keehn and Lowe (2015) and Keehn, Taylor and Lowe (2016): early trials of pygeum, saw palmetto, rye pollen and South African star grass showed mixed results with confounders such as poor product standardisation; more recent, larger, better-built studies of phytotherapy found no significant benefit over placebo, though the agents were largely safe.
• Cicero and colleagues (2019, Italy): pygeum, nettle and pumpkin seed could be considered as add-ons to standard therapies, supported by studies showing improved symptoms and flow measures.
• Salinas-Casado and colleagues (2020, Spain): pygeum "seems to be an option", while explicitly grading the review's own evidence as level IV, expert opinion.
• Arnold and colleagues (2023, US family medicine): saw palmetto is not effective, but pygeum and beta-sitosterol "may be effective".

The abstracts of the sceptical reviews do not say which herbs the larger, newer trials tested, and no new large pygeum trial appears in the evidence gathered for this page. The reviewers are largely reinterpreting the same older pygeum data, which is how they can reach different conclusions from it.

Back to Table of Contents

Where Standard Treatment Sits

For context, the reviews in the pack describe the conventional options against which any herbal treatment is implicitly measured:

• Self-management — the 2023 review listed limiting evening fluids, cutting caffeine and alcohol, bladder training, pelvic floor exercises and mindfulness techniques as methods that can improve symptoms.
• Alpha-blockers — described in the 2023 review as primary medical treatment, offering rapid benefit.
• 5-alpha-reductase inhibitors — for larger prostates, taking up to a year for full effect.
• Phosphodiesterase-5 inhibitors — another primary option in the 2023 review.
• Surgery — needed by only about 1% of men with lower urinary tract symptoms, according to the same review.

A 2013 French review of urinary drugs reported that alpha-blockers and 5-alpha-reductase inhibitors have clearer efficacy than plant extracts for BPH symptoms. Because no trial compared pygeum directly with any of these, there is no measured answer to how it ranks among them.

Back to Table of Contents

What Has Never Been Tested

• Long-term outcomes. No controlled trial in the pack lasted longer than about four months; whether pygeum changes the course of BPH, such as the risk of urinary retention or surgery, is unknown. The Cochrane and 2000 reviewers both called for studies of long-term effectiveness and prevention of complications.
• Prostate size. The reviews report symptom and flow changes; there is no pack evidence that pygeum shrinks the prostate in men.
• Head-to-head comparisons with standard drugs or with other herbs.
• Drug interactions and safety in men also taking BPH drugs.
• Modern, large placebo-controlled trials using the IPSS and lasting a year or more.

These gaps matter most for men deciding between a herbal product and a standard treatment, a choice that belongs with a clinician who can also rule out other causes of urinary symptoms.

Back to Table of Contents

Key Research Papers

1. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. The Cochrane database of systematic reviews. 2002;1998(1):CD001044. PubMed PMID: 11869585
2. Ishani A, MacDonald R, Nelson D, et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. The American journal of medicine. 2000;109(8):654-64. PubMed PMID: 11099686
3. Wilt TJ, Ishani A, Rutks I, et al. Phytotherapy for benign prostatic hyperplasia. Public health nutrition. 2000;3(4A):459-72. PubMed PMID: 11276294
4. Barlet A, Albrecht J, Aubert A, et al. [Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study]. Wiener klinische Wochenschrift. 1990;102(22):667-73. PubMed PMID: 1702916
5. Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology. 1999;54(3):473-8. PubMed PMID: 10475357
6. Arnold MJ, Gaillardetz A, Ohiokpehai J. Benign Prostatic Hyperplasia: Rapid Evidence Review. American family physician. 2023;107(6):613-622. PubMed PMID: 37327163
7. McNicholas T, Kirby R. Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ clinical evidence. 2011;2011. PubMed PMID: 21871136
8. Dreikorn K. Phytotherapeutic agents in the treatment of benign prostatic hyperplasia. Current urology reports. 2000;1(2):103-9. PubMed PMID: 12084323
9. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World journal of urology. 2002;19(6):426-35. PubMed PMID: 12022711
10. Morán E, Budía A, Broseta E, et al. [Phytotherapy in urology. Current scientific evidence of its application in benign prostatic hyperplasia and prostate adenocarcinoma]. Actas urologicas espanolas. 2013;37(2):114-9. PubMed PMID: 23058996
11. Keehn A, Lowe FC. Complementary and alternative medications for benign prostatic hyperplasia. The Canadian journal of urology. 2015;22 Suppl 1:18-23. PubMed PMID: 26497340
12. Keehn A, Taylor J, Lowe FC. Phytotherapy for Benign Prostatic Hyperplasia. Current urology reports. 2016;17(7):53. PubMed PMID: 27180172
13. Cicero AFG, Allkanjari O, Busetto GM, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. 2019;91(3). PubMed PMID: 31577095
14. Salinas-Casado J, Esteban-Fuertes M, Carballido-Rodríguez J, et al. Review of the experience and evidence of Pygeum africanum in urological practice. Actas urologicas espanolas. 2020;44(1):9-13. PubMed PMID: 31627963
15. Game X, Cornu JN, Robert G, et al. [Drug therapy of urethral diseases]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2013;23(15):1287-98. PubMed PMID: 24183087

PubMed Topic Searches

1. PubMed: Pygeum africanum randomized controlled trials
2. PubMed: Pygeum africanum International Prostate Symptom Score
3. PubMed: Phytotherapy for BPH systematic reviews

Back to Table of Contents

Connections

• All Herbs
• Pygeum (Prunus africana) — the main topic page
• Pygeum Benefits Hub — all four deep dives
• Bark Chemistry and Mechanisms — what might explain an effect
• Overharvesting and CITES — where the bark comes from
• Pygeum vs Saw Palmetto and Nettle — the three herbs compared
• Saw Palmetto: Prostate Health and BPH — the larger trials
• Nettle Root for Prostate and BPH — another BPH herb
• Benign Prostatic Hyperplasia — the condition and its standard treatments
• Frequent Urination — causes beyond the prostate
• Overactive Bladder — overlapping symptoms
• PSA Test — the prostate blood test
• Pumpkin Seeds: Prostate and Urinary Health — a food-based comparison

Back to Table of Contents